Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

NCT02014259 · Completed

Last updated 2026-05-28

This clinical trial tested how a diabetes medication called semaglutide is absorbed and processed in people with different levels of kidney function, including those with healthy kidneys.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 71 people

Who can join Ages 18–85 · all sexes Healthy volunteers accepted.

Timeline Started 2013-12 · est. completion 2014-10

Where 4 sites · Czechia, Hungary

What this study is testing ClinicalTrials.gov NCT02014259 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide in subjects with various degrees of impaired renal function compared to subjects with normal renal function.

Treatments tested

semaglutide Drug

Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg

Main thing measured	Area under the semaglutide plasma concentration time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02014259 ↗